COMMUNIQUÉS West-GlobeNewswire

-
Aveanna Healthcare Holdings Announces Appointment of Chief Legal Officer and Secretary
03/04/2024 -
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/04/2024 -
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/04/2024 -
TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors
03/04/2024 -
MannKind Repays Certain Debt Obligations
03/04/2024 -
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases
03/04/2024 -
RadNet Announces a Proposed Refinancing of its Term Loan and Revolving Credit Facility
03/04/2024 -
GUERBET : Mise à disposition du Document d’enregistrement universel 2023
03/04/2024 -
Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
03/04/2024 -
iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024
03/04/2024 -
CancerVax Launches $5 Million Funding Round
03/04/2024 -
EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)
03/04/2024 -
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC
03/04/2024 -
Pharming Group to participate in April investor conferences
03/04/2024 -
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
03/04/2024 -
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
03/04/2024 -
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
03/04/2024 -
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
03/04/2024 -
Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)
03/04/2024
Pages